FDA Review Raises Questions About Replimune’s Melanoma Therapy Ahead of Advisory Committee Vote
As reported on Reuters, Replimune’s experimental cancer treatment RP1 is facing increased regulatory scrutiny after U.S. Food and Drug Administration (FDA) reviewers expressed concerns about whether current clinical data adequately…
Continue Reading
FDA Review Raises Questions About Replimune’s Melanoma Therapy Ahead of Advisory Committee Vote
